Information for Health Care Professionals
Health care providers play a critical role in sharing information with their patients about COVID-19 and immunization. Provincial Factsheets for the various COVID-19 vaccines can be located at that Resources and Consent Forms. Additional information on vaccine development, Canada's authorized vaccines and clinic planning is available through the federal government’s COVID-19 Vaccination Tool Kit for Health Care Providers and Planning Guidance for Immunization Clinics for COVID-19 Vaccines.
Manitoba COVID-19 Vaccine: Clinical Practice Guidelines for Immunizers and Health Care Providers (pdf, May 3, 2022) NOTE: the Clinical Practice Guidelines document is being transitioned to a historical reference document and is no longer being updated. New resources for health care providers will replace this document in the coming weeks. In the meantime, please continue to refer to the most recent memos for current provincial guidance.
COVID-19 Vaccines Storage and Handling Quick Reference (January 03, 2023) is for all health care providers who administer COVID-19 vaccines to review and reference the storage and handling requirements for the COVID-19 vaccines in Manitoba by product. The information is also available within the product monographs.
Quick Reference Guides for Immunizers
mRNA / non-mRNA vaccines COVID-19 Vaccines and Influenza and Pneumococcal Vaccines Approved for Use in Canada: 2022-2023. This document can be used by immunization providers to help with providing the information needed on each product.
mRNA/non-MRNA vaccines COVID-19 TARIFF included chart
More information:
Pfizer Pediatric BA.4/5 Bivalent COVID-19 Vaccine for 5 to 11 year olds (pdf, December 9, 2022)
Updated Clinical Recommendations on Concurrent Administration of Vaccines for Children 6 months to 4 years old and Management of Radiocontrast Allergies and COVID-19 Vaccine Administration (pdf, December 9, 2022)
Replacement of Expiring COVID-19 Vaccine: Pfizer/ComirnatyTM Monovalent 30mcg Product (Purple cap) with Pfizer/ComirnatyTM Monovalent 30mcg Product (Grey cap) (pdf, November 15, 2022)
COVID-19 Vaccine: Prioritization of Moderna/Spikevax™ Infant Pediatric for second doses and primary series of immunocompromised children aged 6 months to ≤ 4 years (pdf, November 08, 2022)
Recommendations for COVID-19 Vaccine Booster Doses for Pregnant and Breastfeeding Individuals (pdf, November 02, 2022)
COVID-19 Vaccine: Approval of Pfizer/ComirnatyTM Infant Pediatric and guidance for children aged 6 months to ≤ 4 years (pdf, October 28, 2022)
Bivalent COVID-19 Vaccine: Approval, Eligibility and Guidance (pdf, October 13, 2022)
Bivalent COVID-19 Vaccine: Expanded Eligibility (pdf, September 21, 2022)
Bivalent COVID-19 Vaccine: Approval, Eligibility and Guidance (pdf, September 09, 2022)
COVID-19: Communication to Providers Regarding Booster Doses (pdf, July 21, 2022)
COVID-19 Vaccine: approval/guidance for children aged 6 months to ≤ 4 years (pdf, July 20, 2022)
Manitoba COVID-19 Vaccine: Novavax, 12-17 year old and 18+ First Boosters (pdf, April 13, 2022)
Manitoba COVID-19 Vaccine: Second Booster Recommendations and Moderna for 6-11 years of age (pdf, April 6, 2022)
COVID-19 Vaccine: Booster Dose Guidance for Adolescents (pdf, February 4, 2022)
COVID-19 Vaccine: Clarifying Recommended and Minimum Intervals (pdf, January 12, 2022)
COVID-19 Vaccine: Moderna for individuals aged ≥ 30 years (pdf, December 31, 2021)
COVID-19 Vaccine: updated third/booster dose interval for individuals aged ≥ 50 years and updated vaccine product for individuals aged ≥ 30 years (pdf, December 24, 2021)
COVID-19 Vaccine: updated third/booster dose guidance and preferential use of Pfizer/ComirnatyTM for 12 to 29 year olds (pdf, December 10, 2021)
COVID-19 Vaccine: Approval/Guidance for Children aged five to ≤ 11 years (pdf, November 23, 2021)
COVID-19 Vaccine Update: Pharmacists to Start Administering COVID-19 and Influenza Vaccines to Those Five Years of Age and Older (pdf, November 16, 2021)
COVID-19 Vaccine Update: Expanded Third/ Booster Dose 6 Months After Dose 2 Guidance (pdf, November 10, 2021)
COVID-19 Vaccine: Third/Booster Dose Update (pdf, November 5, 2021)
COVID-19 Vaccine RE: Important Program Updates (pdf, November 3, 2021)
Moderna/Spikevax - Shelf life extension for US Labeled 14 dose vials (pdf, October 29, 2021)
COVID-19 Vaccine: Booster/Third Dose Guidance and Expansion to Include Residents of Congregate Elderly Person Housing Sites (pdf, October 27, 2021)
COVID-19 Vaccine Medical Exemption Program (pdf, October 6, 2021)
COVID-19 Vaccine: Expansion of Third Doses to Health Care Personnel and to People who received a Viral Vector Vaccine Series (pdf, October 5, 2021)
Manitoba Adopting National Advisory Committee on Immunization (NACI) Guidance (pdf, October 1, 2021)
COVID-19 Vaccine Guidance for Personal Care Homes: Recommended Interval between Second and Third Doses of COVID-19 Vaccine & Update on COVID-19/Flu Vaccine Sequence of Administration (pdf, September 23, 2021)
COVID-19 Vaccine: Expansion of Third Doses to Personal Care Homes (pdf, September 20, 2021)
COVID-19 Vaccine: Additional Information on Third Doses (pdf, September 17, 2021)
COVID-19 Vaccine: Additional mRNA Vaccine Dose for Certain Populations and Medical Exemption Program (pdf, September 15, 2021)
Reporting COVID-19 and School Vaccine Doses Administered to Clients without a PHIN (pdf, September 2021)
Pfizer - Shelf life extension for identified lots in Ultra Low Temperature Storage (pdf, August 30, 2021)
COVID-19 Vaccine: Recommendations for Immunizing Adolescents (pdf, August 2021)
COVID-19 Vaccine: Updated Age Eligibility Criteria for Children (pdf, August 2021)
COVID-19 Vaccine: Allergy Assessment and Referral (pdf, June 2021)
IMPORTANT NOTICE: Effective immediately, pause use of AstraZeneca / COVISHIELD in People aged < 55 years (pdf, March 29, 2021)
First Nations Identification for the Purpose of Booking AstraZeneca/ Covishield Vaccination (pdf, March 29, 2021)
Manitoba COVID-19 Vaccine: Updated AstraZeneca and COVISHIELD Product Monographs and Health Product Risk Communication (pdf, March 25, 2021)
Health Product Risk Communication: Important Safety Information on AstraZeneca and COVISHIELD Vaccines (pdf, March 24, 2021)
COVID-19 Vaccine: New/Updated Communications Products including Clinical Practice Guidelines and Consent Form (pdf, March 15, 2021)
COVID-19 Vaccine: Guidance for Immunizers to Select the Reason for Immunization (pdf, March 2, 2021)
Memo to Health Care Providers on Enhanced Consent (pdf, January 25, 2021)
Pfizer BioNTech - Information for health care providers (manufacturer site)
CanVax: COVID-19 Vaccine Questions and Answers for Healthcare Providers
Memo to Health Care Providers (pdf, December 15, 2020)
